W. Martin Kast
Loyola University-Chicago

About this Book

The field of peptide based cancer vaccines has evolved tremendously in the last decade of this century. The exploration on how to apply the peptide knowledge for vaccination purposes began when it was demonstrated that these peptides after being mixed into adjuvants actually induced T cell responses that could prevent virus infections and tumor growth in experimental animal models. The results of animal models are currently translated into clinical applications with all their associated difficulties and heterogeneity. Initial promising data do appear, warranting further research in this area. This book pays tribute to key researchers in the field.

Table of Contents

Identification and Selection of T-Cell Epitopes Derived from Tumor-Associated Antigens for the Development of Immunotherapy for Cancer
Esteban Celis

Mutant Oncogene and Tumor Suppressor Gene Products and Fusion Proteins Created by Chromosomal Translocations as Targets for Cancer Vaccines
V. Ellen Maher, B. Scott Worley, David Contois, M. Charles Smith,
Michael J. Kelley, Michael Stipanov, Samir N. Khleif, Theresa Goletz, Leon van den Broeke, Crystal Mackall, Lee J. Helman, David P. Carbone, and Jay A. Berzofsky

p53: A Target for T-Cell Mediated Immunotherapy
Michel P.M. Vierboom, Dmitry I. Gabrilovich, Rienk Offringa, W. Martin Kast
and Cornelis J.M. Melief

Critical Dependence of the Peptide Delivery Method on the Efficacy of Epitope Focused Immunotherapy
Gregory E. Holt, Markwin P. Velders, Michael P. Rudolf, Laurie A. Small,
Maurizio Provenzano, Sanne Weijzen, Diane Da Silva, Marten Visser, Simone ter Horst,
Remco M.P. Brandt, and W. Martin Kast

Cancer Peptide Vaccines in Clinical Trials
Jeffrey Weber

Carcinoembryonic Antigen (CEA) Peptides and Vaccines for Carcinoma
Jeffrey Schlom

Studies of MUC1 Peptides
Vasso Apostolopoulos, Dr. Geoffrey Pietersz and Ian FC McKenzie

Cytotoxic T Cell Epitopes and Tissue Distribution of the HER-2/neu Proto-Oncogene: Implications for Vaccine Development
Seliger, K. Kono, Y. Rongcun and R. Kiessling

Clinical Trials of HER-2/neu Peptide-Based Vaccines
Mary L. Disis and Martin A. Cheever

Peptides In Prostate Cancer
Michael L. Salgaller

Peptides In Cervical Cancer
Maaike E. Ressing, Remco M.P. Brandt, Joan H. de Jong, Rienk Offringa,
Cornelis J.M. Melief and W. Martin Kast

Peptide Vaccines for the Treatment of Melanoma
Willem W. Overwijk and Nicholas P.Restifo

Gp100 and G250: Towards Specific Immunotherapy Employing Dendritic Cells
in Melanoma and Renal Cell Carcinoma
Joost L.M.Vissers, I. Jolanda M. de Vries, Egbert Oosterwijk, Carl G. Figdor
and Gosse J. Adema

Melanoma Peptide Clinical Trials
Ian D. Davis and Michael T. Lotze